Medtronic next-gen Cardioblate BP cleared by FDA
This article was originally published in The Gray Sheet
Executive Summary
Firm plans to commence a clinical trial to examine device effectiveness in treating chronic atrial fibrillation this autumn, Medtronic states Aug. 6, following July clearance of the bipolar radiofrequency ablation system for surgical procedures. The more specific indication, for which the firm plans to seek agency go-ahead, following trial completion in 2004, would allow Medtronic to market the device specifically for AF. The single-electrode, first-generation device was first cleared in February 2002 (1'The Gray Sheet" Feb. 4, 2002, In Brief)...
You may also be interested in...
Cardioblate BP in Europe
Medtronic surgical ablation system earns CE mark for treatment of atrial fibrillation, company announces during European Association of Thoracic Surgeons sessions Oct. 14 in Vienna. The system features a transmurality feedback mechanism that alerts surgeons when the ablation line passes all the way through the tissue, the company notes. Medtronic earned FDA clearance for the device in February 2002 and plans to complete a trial in support of an AF indication in 2004 (1"The Gray Sheet" Aug. 11, 2003, In Brief)...
Medtronic Cardioblate
Surgical radiofrequency "pen" system gains FDA market go-ahead for general ablation of cardiac tissue to neutralize "troublesome electrical activity," firm announces Jan. 29. The device incorporates delivery of an electrolytic irrigation solution to cool the outer tissue and allow deeper heat penetration to improve ablation effectiveness, company explains. Medtronic plans to pursue a specific indication for chronic atrial fibrillation with the "Maze" procedure later this year...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.